ISRCTN17498868已完成1 期
A phase I study evaluating the safety and immunogenicity of a new TB vaccine MVA85A, in healthy volunteers with no evidence of infection with mycobacterium tuberculosis, in Cape Town
niversity of Oxford (UK)0 个研究点目标入组 36 人开始时间: 2008年1月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Healthy adults aged 18 to 50 years (for the first 2 arms), either sex
- •2. Healthy adolescents (aged 12 - 14) for the third arm of the study, either sex
- •3. Screening Elispot negative (less than 17 spots/million PBMC) in all three ESAT6 pools and all three CFP10 pools
- •4. Mantoux test less than 15 mm (less than 10 mm if BCG negative)
- •5. Chest x-ray (CXR) normal with no evidence of active or past TB
- •6. For females only, willingness to practice continuous effective contraception during the study and a negative pregnancy test on the day of vaccination
- •7. Agreement to refrain from blood donation during the course of the study
- •8. Written informed consent
- •9. Willingness to undergo a human immunodeficiency virus (HIV) test
排除标准
- •1. Any deviation from the normal range in biochemistry or haematology blood tests or in urine analysis
- •2. Mantoux greater than 15 mm
- •3. Prior receipt of a recombinant MVA or Fowlpox vaccine
- •4. Use of any investigational or non-registered drug, live vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period
- •5. Administration of chronic (defined as more than 14 days) immunosuppressive drugs or other immune modifying drugs within six months of vaccination (for corticosteroids, this will mean prednisolone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
- •6. Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection and asplenia
- •7. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products
- •8. Evidence of cardiovascular disease
- •9. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
- •10. History of diabetes mellitus
- •11. Chronic or active neurological disease requiring ongoing specialist or medical supervision
- •12. Chronic gastrointestinal disease requiring ongoing specialist or medical supervision
- •13. History of greater than two hospitalisations for invasive bacterial infections (pneumonia, meningitis)
- •14. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
- •15. Seropositive for hepatitis B surface antigen (HBsAg)
- •16. Seropositive for hepatitis C virus (antibodies to HCV)
- •17. Evidence of serious psychiatric condition
- •18. Any other ongoing chronic illness requiring hospital specialist or medical supervision
- •19. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- •20. Pregnant or lactating female
- •21. Female who is willing or intends to become pregnant during the study
- •22. Any history of anaphylaxis in reaction to vaccination
- •23. Inability to give informed consent
- •24. PI assessment of lack of willingness to participate and comply with all requirements of the protocol
- •25. Any other finding which in the opinion of the investigator would significantly increase the risk of having an adverse outcome from participating in this protocol
研究者
相似试验
进行中（未招募）
1 期
A phase I study to evaluate safety and immunogenicity of recombinant protein candidate vaccine against SARS-CoV-2 in healthy volunteers.SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862EUCTR2021-001411-82-ESABORATORIOS HIPRA, S.A.30
进行中（未招募）
1 期
A study of a new vaccine against the MERS virus in adults aged 50 to 70 yearsMiddle East Respiratory Syndrome Coronavirus (MERS-CoV) infectionInfections and InfestationsISRCTN17936606niversity of Oxford84
进行中（未招募）
1 期
Investigating a vaccine against plaguePlagueInfections and InfestationsISRCTN41077863niversity of Oxford36
进行中（未招募）
1 期
A first-in-human study to assess the safety of an MVA-based vaccine for Crimean-Congo Haemorrhagic Fever (MVA-CCHF) and the vaccine's ability to generate an immune responseCrimean-Congo Haemorrhagic FeverInfections and InfestationsISRCTN14935155niversity Hospital Southampton NHS Foundation Trust18
尚未招募
不适用
Malaria vectored vaccines and EPI co-administration trial (VAC 058)MalariaPACTR201402000749217THE JENNER INSTITUTE, UNIVERSITY OF OXFORD65